Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

Abstract Background Previous analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this finding persisted when analysing a longer time period...

Full description

Bibliographic Details
Main Authors: Oliver Reich, Martin K. Schmid, Roland Rapold, Lucas M. Bachmann, Eva Blozik
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Ophthalmology
Subjects:
Claims data
Health insurance
Cost analysis
Macular degeneration
Aflibercept
Ranibizumab
Online Access:http://link.springer.com/article/10.1186/s12886-017-0617-x

Similar Items

Similar Items